转自：广东省市场监督管理局网站 | 序 号 | 案件名称 | 参与集中的经营者 | 审结时间 | | --- | --- | --- | --- | | 1 | 易方达私募基金管理有限公司与珠海润合智汇医药投资有限公司新设合 | 易方达私募基金管理有限公司、珠海润合智汇医药投资有限公司 | 2026年2月 | | | 营企业案 | | 9日 | | 2 | 广州医药股份有限公司收购浙江省医药工业有限公司股权案 | 广州医药股份有限公司、浙江省医药工业有限公司 | 2026年2月 11日 | | | 国投交通控股有限公司与海南省洋浦开发建设控股有限公司收购国投裕 | 国投交通控股有限公司、海南省洋浦开发建设控股有限公司、国 | 2026年2月 | | 3 | 廊洋浦港口有限公司股权案 | 投裕廊洋浦港口有限公司 | 11日 | | 4 | 广州工业投资控股集团有限公司收购宁波旭升集团股份有限公司股权案 | 广州工业投资控股集团有限公司、宁波旭升集团股份有限公司 | 2026年2月 13日 | ...

浙江医药（600216）(600216.SH)发布公告，2026年2月24日，公司与普通合伙人中信医疗健康股权投资 私募基金管理(北京)有限公司、有限合伙人廊坊市主导产业投资引导基金有限公司等签署《廊坊信慧银 发经济股权投资基金合伙企业(有限合伙)之合伙协议》，共同投资廊坊信慧银发经济股权投资基金合伙 企业(有限合伙)，合伙企业的全部认缴出资额为8亿元，公司作为有限合伙人以自有资金认缴出资2.5亿 元，占合伙企业认缴出资总额的31.25%。 合伙企业由中信医疗健康股权投资私募基金管理(北京)有限公司担任普通合伙人、执行事务合伙人和基 金管理人。合伙企业重点投向银发经济/医药大健康领域的目标公司，促使被投资企业价值迅速提升， 实现基金的设立目标，同时尽合理商业努力获得本基金资本的增值，并努力实现全体合伙人收益的最大 化，从而实现多赢的结果。 ...

合伙企业由中信医疗健康股权投资私募基金管理(北京)有限公司担任普通合伙人、执行事务合伙人和基 金管理人。合伙企业重点投向银发经济/医药大健康领域的目标公司，促使被投资企业价值迅速提升， 实现基金的设立目标，同时尽合理商业努力获得本基金资本的增值，并努力实现全体合伙人收益的最大 化，从而实现多赢的结果。 智通财经APP讯，浙江医药(600216.SH)发布公告，2026年2月24日，公司与普通合伙人中信医疗健康股 权投资私募基金管理(北京)有限公司、有限合伙人廊坊市主导产业投资引导基金有限公司等签署《廊坊 信慧银发经济股权投资基金合伙企业(有限合伙)之合伙协议》，共同投资廊坊信慧银发经济股权投资基 金合伙企业(有限合伙)，合伙企业的全部认缴出资额为8亿元，公司作为有限合伙人以自有资金认缴出 资2.5亿元，占合伙企业认缴出资总额的31.25%。 ...

Group 1 - The core viewpoint of the article is that 康龙化成 (300759.SZ) is increasing its investment in 宁波甬康 by 50 million RMB to enhance its investment capabilities and promote high-quality development in the pharmaceutical industry [1] - After this additional investment, the total contribution of the company to 宁波甬康 will amount to 150 million RMB, representing 87.1343% of the total subscribed capital of the fund [1] - The company signed a limited partnership agreement regarding 宁波甬康 on January 9, 2026 [1]

Overview - The company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has participated in the establishment of a private equity investment fund named "China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership)" [2] Group 1 - On October 28, 2025, the company signed a partnership agreement with 11 other investors to jointly establish the fund [2] - The fund has completed its registration with the Asset Management Association of China [3] - The fund is managed by Shenzhen China Resources Capital Equity Investment Co., Ltd. and is custodied by China Merchants Bank Co., Ltd. [3]

Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference will be held on October 26-27, 2025, in Nanjing, focusing on global pharmaceutical frontiers and capital trends, gathering top minds in the pharmaceutical innovation and investment fields [1][2]. Conference Information - The conference will take place at Fengda International Hotel, Nanjing, and will cover multiple thematic forums including innovative drug research and development, clinical research, cell and gene therapy, investment mergers and acquisitions, capital markets, and commercial insurance policies [2]. - The agenda includes various sub-forums such as cell and gene therapy, weight loss innovation, clinical data, anti-tumor new drugs, and international roadshows, ensuring comprehensive coverage of the pharmaceutical industry [3][4]. Key Topics - The conference will address core challenges and development trends in the pharmaceutical industry, emphasizing internationalization, investment financing, and regulatory policies, with a focus on the synergy between basic medical insurance and commercial health insurance [5]. - Discussions will include the strategies of Chinese innovative pharmaceutical companies in global markets, particularly in terms of licensing, mergers, and new investment trends [5][6]. Expert Participation - The conference will feature senior experts, clinical specialists, industry leaders, and frontline investors who will share insights on breakthrough technologies, practical experiences in investment mergers, and policy interpretations [4][6]. - Notable speakers include leaders from prestigious institutions and companies, contributing to discussions on the construction of innovative ecosystems and cross-sector collaboration [4][6]. Forum Structure - The conference will be structured around multi-dimensional forums designed to promote deep dialogue and knowledge sharing across clinical, industrial, capital, and policy fields, with three core discussion directions: global strategic layout, capital collaborative innovation, and market trend outlook [6].

Group 1 - The company announced the establishment of a new partnership for investment in the pharmaceutical industry, involving its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. [1] - The total committed capital for the new partnership, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), is set at 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total commitment [1]

Core Viewpoint - East China Pharmaceutical (000963.SZ) aims to enhance its industrial investment ecosystem and expand its industry chain layout by establishing a partnership with Shanghai Fuguang Private Fund Management Co., Ltd. and other investors to create a specialized pharmaceutical industry investment fund totaling RMB 2 billion [1] Group 1: Investment Details - The total committed capital for the specialized pharmaceutical industry investment fund is RMB 2 billion, with East China Pharmaceutical contributing RMB 980 million, representing a 49% stake [1] - The fund will focus on investment areas including innovative drugs, medical aesthetics, health and wellness, animal health, and sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]